• Something wrong with this record ?

Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration

B. Michelsen, U. Lindström, C. Codreanu, A. Ciurea, J. Zavada, AG. Loft, M. Pombo-Suarez, F. Onen, TK. Kvien, Z. Rotar, MJ. Santos, F. Iannone, AM. Hokkanen, B. Gudbjornsson, J. Askling, R. Ionescu, MJ. Nissen, K. Pavelka, C. Sanchez-Piedra, S....

. 2020 ; 6 (3) : . [pub] -

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21026603

OBJECTIVES: To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) time since diagnosis and (3) different European registries. METHODS: Real-life data from 13 European registries participating in the European Spondyloarthritis Research Collaboration Network were pooled. Kaplan-Meier with log-rank test, Cox regression, χ² and logistic regression analyses were performed to assess 6-month and 12-month secukinumab retention, inactive disease/low-disease-activity states (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) <2/<4, Ankylosing Spondylitis Disease Activity Score (ASDAS) <1.3/<2.1) and response rates (BASDAI50, Assessment of Spondyloarthritis International Society (ASAS) 20/40, ASDAS clinically important improvement (ASDAS-CII) and ASDAS major improvement (ASDAS-MI)). RESULTS: We included 1860 patients initiating secukinumab as part of routine care. Overall 6-month/12-month secukinumab retention rates were 82%/72%, with significant (p<0.001) differences between the registries (6-month: 70-93%, 12-month: 53-86%) and across number of previous b/tsDMARDs (b/tsDMARD-naïve: 90%/73%, 1 prior b/tsDMARD: 83%/73%, ≥2 prior b/tsDMARDs: 78%/66%). Overall 6-month/12-month BASDAI<4 were observed in 51%/51%, ASDAS<1.3 in 9%/11%, BASDAI50 in 53%/47%, ASAS40 in 28%/22%, ASDAS-CII in 49%/46% and ASDAS-MI in 25%/26% of the patients. All rates differed significantly across number of previous b/tsDMARDs, were numerically higher for b/tsDMARD-naïve patients and varied significantly across registries. Overall, time since diagnosis was not associated with secukinumab effectiveness. CONCLUSIONS: In this study of 1860 patients from 13 European countries, we present the first comprehensive real-life data on effectiveness of secukinumab in patients with axSpA. Overall, secukinumab retention rates after 6 and 12 months of treatment were high. Secukinumab effectiveness was consistently better for bionaïve patients, independent of time since diagnosis and differed across the European countries.

Amsterdam University Medical Centres VU University Medical Centre Department Rheumatology and Immunology Center Amsterdam Netherlands

biorx si and the Department of Rheumatology University Medical Centre Ljubljana Ljubljana Slovenia

Centre for Rheumatology Research University Hospital and Faculty of Medicine University of Iceland Reykjavik Iceland

Clinical Epidemiology Division Department of Medicine Solna Karolinska Institutet Stockholm Sweden

Copenhagen Center for Arthritis Research Center for Rheumatology and Spine Diseases Centre for Head and Orthopedics Rigshospitalet Glostrup Copenhagen Denmark

DANBIO Registry Center for Rheumatology and Spine Diseases Centre for Head and Orthopaedics Rigshospitalet Glostrup Copenhagen Denmark

Department of Clinical Medicine University of Copenhagen Copenhagen Denmark

Department of Rheumatology Aarhus University Hospital Aarhus Denmark

Department of Rheumatology and Inflammation Research Institute of Medicine Sahlgrenska Academy University of Gothenburg Gothenburg Sweden

Department of Rheumatology Diakonhjemmet Hospital Oslo Norway

Department of Rheumatology Geneva University Hospital Geneve Switzerland

Department of Rheumatology Izmir Kâtip Çelebi University Izmir Turkey

Department of Rheumatology Landspitali University Hospital Reykjavik Iceland

Department of Rheumatology University Hospital Zurich Zurich Switzerland

Division of Rheumatology Department of Medicine Hospital of Southern Norway Trust Kristiansand Norway

Epidemiology Group School of Medicine Medical Science and Nutrition University of Aberdeen Aberdeen UK

GISEA Registry Rheumatology Unit DETO University of Bari Bari Italy

Institute of Rheumatology and Department of Rheumatology 1st Faculty of Medicine Charles University Prague Czech Republic

Institute of Rheumatology Prague Czech Republic

Research Unit Spanish Society of Rheumatology Madrid Spain

Reuma pt Registry and Instituto De Medicina Molecular Faculdade De Medicina Universidade De Lisboa Lisboa Lisboa Portugal

Reuma pt registry and Instituto Português de Reumatologia Lisbon Portugal

Rheumatology Service Hospital Clinico Universitario Santiago De Compostela Spain

Rheumatology Unit CHIMOMO Azienda Policlinico of Modena University of Modena Modena Italy

ROB FIN Registry Helsinki University and Helsinki University Hospital Helsinki Finland

TURKBIO Registry Division of Rheumatology Dokuz Eylul University School of Medicine Izmir Turkey

University of Medicine and Pharmacy Carol Davila Bucharest Bucharest Romania

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026603
003      
CZ-PrNML
005      
20211026132754.0
007      
ta
008      
211013s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/rmdopen-2020-001280 $2 doi
035    __
$a (PubMed)32950963
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Michelsen, Brigitte $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet Glostrup, Copenhagen, Denmark brigitte.michelsen@regionh.dk $u Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway $u Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
245    10
$a Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration / $c B. Michelsen, U. Lindström, C. Codreanu, A. Ciurea, J. Zavada, AG. Loft, M. Pombo-Suarez, F. Onen, TK. Kvien, Z. Rotar, MJ. Santos, F. Iannone, AM. Hokkanen, B. Gudbjornsson, J. Askling, R. Ionescu, MJ. Nissen, K. Pavelka, C. Sanchez-Piedra, S. Akar, J. Sexton, M. Tomsic, H. Santos, M. Sebastiani, J. Österlund, AJ. Geirsson, G. Macfarlane, I. van der Horst-Bruinsma, S. Georgiadis, CH. Brahe, LM. Ørnbjerg, ML. Hetland, M. Østergaard
520    9_
$a OBJECTIVES: To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) time since diagnosis and (3) different European registries. METHODS: Real-life data from 13 European registries participating in the European Spondyloarthritis Research Collaboration Network were pooled. Kaplan-Meier with log-rank test, Cox regression, χ² and logistic regression analyses were performed to assess 6-month and 12-month secukinumab retention, inactive disease/low-disease-activity states (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) <2/<4, Ankylosing Spondylitis Disease Activity Score (ASDAS) <1.3/<2.1) and response rates (BASDAI50, Assessment of Spondyloarthritis International Society (ASAS) 20/40, ASDAS clinically important improvement (ASDAS-CII) and ASDAS major improvement (ASDAS-MI)). RESULTS: We included 1860 patients initiating secukinumab as part of routine care. Overall 6-month/12-month secukinumab retention rates were 82%/72%, with significant (p<0.001) differences between the registries (6-month: 70-93%, 12-month: 53-86%) and across number of previous b/tsDMARDs (b/tsDMARD-naïve: 90%/73%, 1 prior b/tsDMARD: 83%/73%, ≥2 prior b/tsDMARDs: 78%/66%). Overall 6-month/12-month BASDAI<4 were observed in 51%/51%, ASDAS<1.3 in 9%/11%, BASDAI50 in 53%/47%, ASAS40 in 28%/22%, ASDAS-CII in 49%/46% and ASDAS-MI in 25%/26% of the patients. All rates differed significantly across number of previous b/tsDMARDs, were numerically higher for b/tsDMARD-naïve patients and varied significantly across registries. Overall, time since diagnosis was not associated with secukinumab effectiveness. CONCLUSIONS: In this study of 1860 patients from 13 European countries, we present the first comprehensive real-life data on effectiveness of secukinumab in patients with axSpA. Overall, secukinumab retention rates after 6 and 12 months of treatment were high. Secukinumab effectiveness was consistently better for bionaïve patients, independent of time since diagnosis and differed across the European countries.
650    _2
$a humanizované monoklonální protilátky $7 D061067
650    _2
$a lidé $7 D006801
650    12
$a léčivé přípravky $7 D004364
650    _2
$a registrace $7 D012042
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    12
$a spondylartritida $x farmakoterapie $x epidemiologie $7 D025241
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lindström, Ulf $u Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
700    1_
$a Codreanu, Catalin $u University of Medicine and Pharmacy "Carol Davila", Bucharest, Bucharest, Romania
700    1_
$a Ciurea, Adrian $u Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
700    1_
$a Zavada, Jakub $u Institute of Rheumatology, Prague, Czech Republic
700    1_
$a Loft, Anne Gitte $u DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet Glostrup, Copenhagen, Denmark $u Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
700    1_
$a Pombo-Suarez, Manuel $u Rheumatology Service, Hospital Clinico Universitario, Santiago De Compostela, Spain
700    1_
$a Onen, Fatos $u TURKBIO Registry, Division of Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey
700    1_
$a Kvien, Tore K $u Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
700    1_
$a Rotar, Ziga $u biorx.si and the Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia
700    1_
$a Santos, Maria Jose $u Reuma.pt Registry and Instituto De Medicina Molecular, Faculdade De Medicina, Universidade De Lisboa, Lisboa, Lisboa, Portugal
700    1_
$a Iannone, Florenzo $u GISEA Registry, Rheumatology Unit - DETO, University of Bari, Bari, Italy
700    1_
$a Hokkanen, Anna-Mari $u ROB-FIN Registry, Helsinki University and Helsinki University Hospital, Helsinki, Finland
700    1_
$a Gudbjornsson, Bjorn $u Centre for Rheumatology Research (ICEBIO), University Hospital and Faculty of Medicine, University of Iceland, Reykjavik, Iceland
700    1_
$a Askling, Johan $u Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
700    1_
$a Ionescu, Ruxandra $u University of Medicine and Pharmacy "Carol Davila", Bucharest, Bucharest, Romania
700    1_
$a Nissen, Michael J $u Department of Rheumatology, Geneva University Hospital, Geneve, Switzerland
700    1_
$a Pavelka, Karel $u Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Sanchez-Piedra, Carlos $u Research Unit, Spanish Society of Rheumatology, Madrid, Spain
700    1_
$a Akar, Servet $u Department of Rheumatology, Izmir Kâtip Çelebi University, Izmir, Turkey
700    1_
$a Sexton, Joseph $u Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
700    1_
$a Tomsic, Matija $u biorx.si and the Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia
700    1_
$a Santos, Helena $u Reuma.pt registry and Instituto Português de Reumatologia, Lisbon, Portugal
700    1_
$a Sebastiani, Marco $u Rheumatology Unit, CHIMOMO, Azienda Policlinico of Modena, University of Modena, Modena, Italy
700    1_
$a Österlund, Jenny $u ROB-FIN Registry, Helsinki University and Helsinki University Hospital, Helsinki, Finland
700    1_
$a Geirsson, Arni Jon $u Department of Rheumatology, Landspitali University Hospital, Reykjavik, Iceland
700    1_
$a Macfarlane, Gary $u Epidemiology Group, School of Medicine, Medical Science and Nutrition, University of Aberdeen, Aberdeen, UK
700    1_
$a van der Horst-Bruinsma, Irene $u Amsterdam University Medical Centres, VU University Medical Centre, Department Rheumatology & Immunology Center (ARC), Amsterdam, Netherlands
700    1_
$a Georgiadis, Stylianos $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet Glostrup, Copenhagen, Denmark
700    1_
$a Brahe, Cecilie Heegaard $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet Glostrup, Copenhagen, Denmark
700    1_
$a Ørnbjerg, Lykke Midtbøll $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet Glostrup, Copenhagen, Denmark
700    1_
$a Hetland, Merete Lund $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet Glostrup, Copenhagen, Denmark $u Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
700    1_
$a Østergaard, Mikkel $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet Glostrup, Copenhagen, Denmark $u Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
773    0_
$w MED00188812 $t RMD open $x 2056-5933 $g Roč. 6, č. 3 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32950963 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132800 $b ABA008
999    __
$a ok $b bmc $g 1715359 $s 1147110
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 6 $c 3 $e - $i 2056-5933 $m RMD open $n RMD Open $x MED00188812
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Archiving options